2,4-Disubstituted Pyrrolidine Orexin Receptor Antagonists
    38.
    发明申请
    2,4-Disubstituted Pyrrolidine Orexin Receptor Antagonists 有权
    2,4-二取代吡咯烷矿物蛋白受体拮抗剂

    公开(公告)号:US20110201652A1

    公开(公告)日:2011-08-18

    申请号:US13124877

    申请日:2009-10-15

    CPC分类号: C07D401/14

    摘要: The present invention is directed to 2,4-disubstituted pyrrolidine amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

    摘要翻译: 本发明涉及作为食欲素受体的拮抗剂的2,4-二取代的吡咯烷酰胺化合物,其可用于治疗或预防涉及食欲肽受体的神经和精神病症和疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及食欲肽受体的疾病中的用途。

    Prodrugs of mitotic kinesin inhibitors
    40.
    发明授权
    Prodrugs of mitotic kinesin inhibitors 失效
    有丝分裂驱动蛋白抑制剂的前药

    公开(公告)号:US07718687B2

    公开(公告)日:2010-05-18

    申请号:US11630303

    申请日:2005-06-27

    IPC分类号: A61K31/415 C07D231/06

    CPC分类号: C07D231/06 C07F9/65031

    摘要: The present invention relates to prodrugs of dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.

    摘要翻译: 本发明涉及可用于治疗细胞增殖性疾病,用于治疗与KSP驱动蛋白活性相关的病症和用于抑制KSP驱动蛋白的二氢吡唑化合物的前药。 本发明还涉及包含这些化合物的组合物,以及使用它们治疗哺乳动物癌症的方法。